Coll, R. C. & Schroder, K. Inflammasome components as new therapeutic targets in inflammatory disease. Nat. Rev. Immunol. 25, 22–41 (2025).
Fu, J. & Wu, H. Structural Mechanisms of NLRP3 Inflammasome Assembly and Activation. Annu Rev. Immunol. 41, 301–316 (2023).
Huang, Y., Xu, W. & Zhou, R. NLRP3 inflammasome activation and cell death. Cell Mol. Immunol. 18, 2114–2127 (2021).
Yang, Y., Wang, H., Kouadir, M., Song, H. & Shi, F. Recent advances in the mechanisms of NLRP3 inflammasome activation and its inhibitors. Cell Death Dis. 10, 128 (2019).
Seok, J. K., Kang, H. C., Cho, Y. Y., Lee, H. S. & Lee, J. Y. Therapeutic regulation of the NLRP3 inflammasome in chronic inflammatory diseases. Arch. Pharm. Res. 44, 16–35 (2021).
Mangan, M. S. J. et al. Targeting the NLRP3 inflammasome in inflammatory diseases. Nat. Rev. Drug Discov. 17, 588–606 (2018).
Soták, M., Clark, M., Suur, B. E. & Börgeson, E. Inflammation and resolution in obesity. Nat. Rev. Endocrinol. 21, 45–61 (2025).
Deng, Y. et al. Obesity Enables NLRP3 Activation and Induces Myocardial Fibrosis via Hyperacetylation of HADHa. Diabetes 72, 1597–1608 (2023).
McManus, R. M. et al. NLRP3-mediated glutaminolysis controls microglial phagocytosis to promote Alzheimer’s disease progression. Immunity 58, 326–343 (2025).
Wang, L. & Hauenstein, A. V. The NLRP3 inflammasome: Mechanism of action, role in disease and therapies. Mol. Asp. Med 76, 100889 (2020).
Yan, L. -j et al. Hypocrellin A from an ethnic medicinal fungus protects against NLRP3-driven gout in mice by suppressing inflammasome activation. Acta Pharmacologica Sin. 46, 1016–1029 (2025).
Ward, R. et al. NLRP3 inflammasome inhibition with MCC950 improves diabetes-mediated cognitive impairment and vasoneuronal remodeling after ischemia. Pharm. Res. 142, 237–250 (2019).
Jia, L. et al. Ginkgolide C inhibits ROS-mediated activation of NLRP3 inflammasome in chondrocytes to ameliorate osteoarthritis. J. Ethnopharmacol. 325, 117887 (2024).
Shan, X. et al. Kai-Xin-San ameliorates Alzheimer’s disease-related neuropathology and cognitive impairment in APP/PS1 mice via the mitochondrial autophagy-NLRP3 inflammasome pathway. J. Ethnopharmacol. 329, 118145 (2024).
Coll, R. C. et al. A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases. Nat. Med. 21, 248–255 (2015).
Tapia-Abellán, A. et al. MCC950 closes the active conformation of NLRP3 to an inactive state. Nat. Chem. Biol. 15, 560–564 (2019).
Jiang, H. et al. Identification of a selective and direct NLRP3 inhibitor to treat inflammatory disorders. J. Exp. Med 214, 3219–3238 (2017).
Marchetti, C. et al. OLT1177, a β-sulfonyl nitrile compound, safe in humans, inhibits the NLRP3 inflammasome and reverses the metabolic cost of inflammation. Proc. Natl. Acad. Sci. USA 115, E1530–E1539 (2018).
Kim, W. et al. A potent NLRP3 inhibitor effective against both MCC950-sensitive and -resistant inflammation. Cell Chem. Biol. 32, 1125–1139 (2025).
Atanasov, A. G., Zotchev, S. B., Dirsch, V. M. & Supuran, C. T. Natural products in drug discovery: advances and opportunities. Nat. Rev. Drug Discov. 20, 200–216 (2021).
Zhang, L., Li, Y., Sun, D. & Bai, F. Protective Effect of Nimbolide against High Fat Diet-induced Obesity in Rats via Nrf2/HO-1 Pathway. J. Oleo Sci. 71, 709–720 (2022).
Gu, Y., Liu, B., Xia, X., Luo, C. & Ren, Y. Chemoprotective effect of nimbolide against N-methyl-N-nitrosourea induced gastric cancer via alteration of apoptosis and NF-κB signaling pathway. Acta Cir. Bras. 40, e402125 (2025).
Israr, M. et al. Nimbolide attenuates complete Freund’s adjuvant induced arthritis through expression regulation of toll-like receptors signaling pathway. Phytother. Res 37, 903–912 (2023).
Shi, J. et al. Cleavage of GSDMD by inflammatory caspases determines pyroptotic cell death. Nature 526, 660–665 (2015).
Di Virgilio, F., Dal Ben, D., Sarti, A. C., Giuliani, A. L. & Falzoni, S. The P2X7 Receptor in Infection and Inflammation. Immunity 47, 15–31 (2017).
Hornung, V. et al. Silica crystals and aluminum salts activate the NALP3 inflammasome through phagosomal destabilization. Nat. Immunol. 9, 847–856 (2008).
Nakahira, K. et al. Autophagy proteins regulate innate immune responses by inhibiting the release of mitochondrial DNA mediated by the NALP3 inflammasome. Nat. Immunol. 12, 222–230 (2011).
He, Y., Zeng, M. Y., Yang, D., Motro, B. & Núñez, G. NEK7 is an essential mediator of NLRP3 activation downstream of potassium efflux. Nature 530, 354–357 (2016).
Hochheiser, I. V. et al. Structure of the NLRP3 decamer bound to the cytokine release inhibitor CRID3. Nature 604, 184–189 (2022).
Xiao, L., Magupalli, V. G. & Wu, H. Cryo-EM structures of the active NLRP3 inflammasome disc. Nature 613, 595–600 (2023).
Feng, S. et al. Mechanisms of NLRP3 activation and inhibition elucidated by functional analysis of disease-associated variants. Nat. Immunol. 26, 511–523 (2025).
Gu, L. et al. NLRP3 promotes inflammatory signaling and IL-1β cleavage in acute lung injury caused by cell wall extract of Lactobacillus casei. Commun. Biol. 8, 20 (2025).
Xue, J. C. et al. Natural products modulate NLRP3 in ulcerative colitis. Front Pharm. 14, 1265825 (2023).
Zhou, J., Yang, Q., Wei, W., Huo, J. & Wang, W. Codonopsis pilosula polysaccharide alleviates ulcerative colitis by modulating gut microbiota and SCFA/GPR/NLRP3 pathway. J. Ethnopharmacol. 337, 118928 (2025).
Wang, Z. et al. Polypharmacology of ambroxol in the treatment of COVID-19. Biosci. Rep. 43, https://doi.org/10.1042/bsr20221927 (2023).
Shi, M. et al. Identification of 18β-glycyrrhetinic acid as an AGT inhibitor against LPS-induced myocardial dysfunction via high throughput screening. Biochem Pharm. 223, 116127 (2024).
Xu, Y. et al. Sirt3 is a novel target to treat sepsis induced myocardial dysfunction by acetylated modulation of critical enzymes within cardiac tricarboxylic acid cycle. Pharm. Res 159, 104887 (2020).
Xu, W. et al. Eurycomanone inhibits osteosarcoma growth and metastasis by suppressing GRP78 expression. J. Ethnopharmacol. 335, 118709 (2024).
Okba, M. M., Ezzat, M. I., Shehabeldine, A. M. & Ezzat, S. M. Eurycomanol and eurycomanone as potent inducers for cell-cycle arrest and apoptosis in small and large human lung cancer cell lines. Nat. Prod. Res. 37, 1856–1862 (2023).
Bosch, J. PPI inhibitor and stabilizer development in human diseases. Drug Discov. Today Technol. 24, 3–9 (2017).
Villar, J. et al. Dexamethasone treatment for the acute respiratory distress syndrome: a multicentre, randomised controlled trial. Lancet Respir. Med 8, 267–276 (2020).
He, H. et al. Oridonin is a covalent NLRP3 inhibitor with strong anti-inflammasome activity. Nat. Commun. 9, 2550 (2018).
Chen, X. et al. Target identification of natural medicine with chemical proteomics approach: probe synthesis, target fishing and protein identification. Signal Transduct. Target Ther. 5, 72 (2020).
Zahid, A., Li, B., Kombe, A. J. K., Jin, T. & Tao, J. Pharmacological Inhibitors of the NLRP3 Inflammasome. Front Immunol. 10, 2538 (2019).
Sharmila, A. et al. Nanoformulated Terpenoids in Cancer: A Review of Therapeutic Applications, Mechanisms, and Challenges. Cancers (Basel) 17, 3013 (2025).